<DOC>
	<DOCNO>NCT02634684</DOCNO>
	<brief_summary>This application seek renew support MH59803 , `` Dopaminergic substrates startle gate across specie , '' extend clear path `` bench-to-bedside '' progress towards critical paradigm shift therapeutic model schizophrenia ( SZ ) schizoaffective disorder , depress type ( SZA ) : use Pharmacologic Augmentation Cognitive Therapies ( PACTs ) . This novel therapeutic strategy SZ/SZA directly address need effective treatment devastate disorder . MH59803 investigate neural regulation laboratory-based measure deficient information processing SZ/SZA patient , use rodent healthy human subject ( HS ) explicate biology deficit , establish rational basis develop novel therapy SZ/SZA . In first 9 year , MH59803 study neural regulation prepulse inhibition ( PPI ) startle rat focus basic neurobiological molecular mechanism . Over past 2 year support , MH59803 study move `` bench-to-bedside , '' focus dopamine ( DA ) agonist effect PPI neurocognition HS , regulation gene identify cross-species study . These study detect biological marker predict PPI-enhancing pro-cognitive effect DA releaser , amphetamine ( AMPH ) human , lead specific prediction AMPH effect PPI , neurocognition Targeted Cognitive Training SZ/SZA patient . If confirm present application , prediction could help transform therapeutic approach SZ/SZA . This renewal application MH59803 thus reflect logical progression study system molecular level , translate first HS , potentially transformative therapeutic model SZ/SZA patient .</brief_summary>
	<brief_title>Pharmacologically-augmented Cognitive Therapies ( PACTs ) Schizophrenia .</brief_title>
	<detailed_description>MH59803 demonstrate AMPH ( 20 mg p.o . ) significantly increase PPI neurocognitive performance ( MATRICS Consensus Cognitive Battery ; MCCB ) HS characterize specific performance-based genetic biomarkers , include val/val genotype rs4680 polymorphism catechol-O-methyltransferase ( COMT ) . Mechanistically-informative result detect study AMPH effect PPI rat high vs. low brain regional Comt expression . Together several report improve neurocognition adverse effect acute sustain AMPH administration antipsychotic ( AP ) -medicated SZ/SZA patient , MH59803 finding provide strong rationale next goal application : test potential utility AMPH paradigm biomarker-informed `` PACTs '' . This `` next step '' highly innovative - never previously report , perhaps even attempt - consistent National Institute Mental Health ( NIMH ) objectives , directly challenge exist model SZ/SZA therapeutic . Investigators determine whether test dose 10-20 mg AMPH p.o . administer biomarker-identified , AP-medicated SZ/SZA patient generate predicted increase PPI , MCCB performance , sensory discrimination learning Targeted Cognitive Training ( TCT ) module . In total , Investigators leverage knowledge generate converge cross-species study MH59803 , directly advance scientific clinical domain , test effect pro-cognitive drug neurophysiological neurocognitive performance , Targeted Cognitive Training , biomarker-stratified subgroup SZ/SZA patient . Aim : To assess acute effect AMPH ( 0 , 10 20 mg po ) PPI , neurocognition computerize TCT AP-medicated SZ/SZA patient . Hypothesis : PPI- MCCB-enhancing effect AMPH see previously HS also detect SZ/SZA patient , TCT-enhancing effect AMPH . Prediction : In within-subject , placebo-controlled , randomized design , AMPH ( 10 and/or 20 mg po ) increase PPI enhance MCCB TCT performance medicate SZ/SZA patient , particularly among characterize low basal performance level and/or val/val rs4680 COMT polymorphism . Concurrent HS test confirm ( 20 mg ) extend ( 10 mg ) finding AMPH effect PPI neurocognition , help interpret finding SZ/SZA patient . In participant , aim ass acute effect 10 mg po dextroamphetamine ( AMPH ) Prepulse Inhibition ( PPI ) , neurocognition MATRICS : Consensus Cognitive Battery ; MCCB , computerize Targeted Cognitive Training ( TCT ) . Hypothesis : AMPH enhance : 1 . PPI 2. neurocognition ( MCCB performance ) 3. computerized TCT performance biomarker-identified SZ/SZA patient . 4 . The PPI MCCB-enhancing effect AMPH see previously HS also detect SZ/SZA patient , TCT-enhancing effect AMPH . Prediction : In within-subject , placebo-controlled , randomized design , AMPH ( 10 and/or 20 mg po ) increase PPI enhance MCCB TCT performance medicate SZ/SZA patient , particularly among characterize low basal performance level and/or val/val rs4680 COMT polymorphism . Concurrent HS test confirm ( 20 mg ) extend ( 10 mg ) finding AMPH effect PPI neurocognition , help interpret finding SZ/SZA patient .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Dextroamphetamine</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Excitatory Amino Acids</mesh_term>
	<mesh_term>Excitatory Amino Acid Antagonists</mesh_term>
	<mesh_term>Molecular Mechanisms Pharmacological Action</mesh_term>
	<criteria>1855 year old : Drug Free ( No recreational/street drug ) Diagnosis Schizophrenia Schizoaffective Disorder , Depressed Type Must stable antipsychotic medication least 1 month Any medication antipsychotic medication need stable least 1 week Dominant hand injury Hearing impairment 40 dB Irregular menstrual cycle cycle within 2535 day ( menopausal eligible ) EKG , conduction abnormality confirm cardiologist Reading component Wide Range Achievement Test 4 ( WRAT4 ) Score le 70 Any serious illness , include : Insulindependent diabetes , HIV , AIDS , cancer , stroke , heart attack , uncontrolled hypothyroidism Sleep apnea A diagnosis epilepsy history seizure loss consciousness Open/closed head injury loss consciousness great 1 minute time lifetime Blood pressure : Systolic Blood Pressure &lt; 90 &gt; 160 , Diastolic Blood Pressure &lt; 45 &gt; 95 Heart Rate &lt; 55 &gt; 110 Current use Dexatrim drug contain phenylephrine ( eligible use least 72 hour prior participation ) Current use St. John 's Wort , Milk Thistle ( eligible least 1 month ) Self report illicit drug use within last 30 day Positive urine toxicology Selfreport use ecstasy , lysergic acid diethylamide ( LSD ) , mushroom , gamma hydroxybutyrate ( GHB ) , ketamine , phencyclidine ( PCP ) , heroin intravenousdrugs within past year If history substance abuse/addiction , participant must remission least 6 month Within 1 month recent psychiatric hospitalization Current mania Dementia/Alzheimer 's diagnosis Mania episode meeting criterion outline MINIInternational Neuropsychiatric Interview Plus 6.0 ( M.I.N.I . plus 6.0 ) anytime lifetime ( hypomania/Bipolar II eligible )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Anti-Dyskinesia Agents</keyword>
	<keyword>Antiparkinson Agents</keyword>
	<keyword>Central Nervous System Agents</keyword>
	<keyword>Dopamine Agents</keyword>
	<keyword>Excitatory Amino Acid Agents</keyword>
	<keyword>Excitatory Amino Acid Antagonists</keyword>
	<keyword>Molecular Mechanisms Pharmacological Action</keyword>
	<keyword>Neurotransmitter Agents</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Prepulse inhibition</keyword>
	<keyword>Neurocognition</keyword>
	<keyword>Working memory</keyword>
	<keyword>Dextroamphetamine</keyword>
	<keyword>MATRICS Consensus Cognitive Battery</keyword>
	<keyword>Pharmacologic Augmentation Cognitive Therapies</keyword>
	<keyword>Sensory discrimination learning</keyword>
	<keyword>Targeted Cognitive Training</keyword>
	<keyword>rs4680 polymorphism catechol-O-methyltransferase ( COMT )</keyword>
</DOC>